Navigation Links
PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research

In Vitro Assays Show rBChE Suppresses Amyloid Plaque Formation

ANNAPOLIS, Md., April 03, 2007 /PRNewswire/ -- PharmAthene, Inc., a leading biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological terrorism, announced today that new data from its recombinant butyrylcholinesterase (rBChE) research program were recently presented at the 8th International Conference on Alzheimer's and Parkinson's Diseases in Salzburg, Austria.

New research conducted by Dr. Hermona Soreq and co-workers at the Alexander Silberman Life Sciences Institute at The Hebrew University of Jerusalem, in collaboration with PharmAthene, examined the role of recombinant butyrylcholinesterase (rBChE) in the formation of amyloid plaques, which are believed to play a crucial role in the development of Alzheimer's disease.

The data presented by Drs. Soreq and Langermann, Vice President and Chief Scientific Officer for PharmAthene, show that rBChE can effectively block the formation of amyloid fibrils, precursors to plaque formation in the brain, potentially attenuating neurotoxicity. These data were substantiated by transmission electron microscopy studies, which showed that rBChE dramatically suppressed the formation of fibrils, resulting in thinner and less branched filaments than would normally occur in patients with Alzheimer's disease.

Alzheimer's disease is a progressive neurodegenerative disease, which is estimated to affect more than 4.5 million Americans. One of the hallmarks of Alzheimer's disease is the accumulation of excessive amyloid plaques in areas of the brain that control memory and cognition. Amyloid fibrils are believed to be neurotoxic and interfere with the normal communication between neurons. A growing body of scientific evidence suggests that the accumulation of amyloid plaques and neurofibrillary tangles in the brain may play an
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmathenes Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimers Research
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
4. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
5. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
6. Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007
7. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
8. CuraGen Presents Update on Clinical Development Program for Belinostat
9. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
10. Diatos Announces Positive Clinical Results for its DTS-201 Doxorubicin Prodrug Program
11. OXiGENE Abstracts Published in ASCO Program
Post Your Comments:
(Date:8/27/2008)...l, expected by mid-2009 - - Data from second Phas...KVILLE, Md., Aug. 27 /- Hum...nounced it has completed enrollment,and initial do...3,randomized clinical trials of LymphoStat-B(R) (b...rythematosus (SLE). Belimumab is being developed b...
(Date:8/26/2008)... SYNTAX clinical trial, NATICK, Mass., Aug. 26 /P...ion (NYSE: BSX ) today announced the schedule of ... at the European Society of Cardiology,Congress 20...nich, Germany., The Company plans to announce 12-...ercutaneous coronary intervention (PCI) using the ...
(Date:8/26/2008)...afore Pharmaceuticals Inc.,presented data at the S...s,in Cancer in Washington, D.C., announcing the di...that demonstrate significant anticancer,activity i...olecular scaffold has been developed using,computa... kinase inhibitors,as well as isoform-selective sm...
(Date:8/26/2008)...- Healthpoint today announced,that it has initiate...f a,widely prescribed enzymatic debriding agent on... pilot study was prompted, in part, by clinical re...rs and beneficial healing,properties associated wi...he findings from the peer-reviewed literature, as ...
Breaking Medicine Technology:Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 2Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 3Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 4Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 3Dubai Provides Aid for Cyclone Nargis Victims In Myanmar 18915 1Dubai Provides Aid for Cyclone Nargis Victims In Myanmar 18915 2Roches Vidal Honored as 2008 HBA Rising Star 18911 1Roches Vidal Honored as 2008 HBA Rising Star 18911 2American Red Cross of Southeastern Michigan Celebrates Outstanding Volunteers for Years of Service 18906 1American Red Cross of Southeastern Michigan Celebrates Outstanding Volunteers for Years of Service 18906 2International Center for Adult Stem Cell Education Debuts at Spinal Cord Injury Symposium in Greece 5268 1International Center for Adult Stem Cell Education Debuts at Spinal Cord Injury Symposium in Greece 5268 2
...-Apr 16, 2007 - Amgen,(Nasdaq:AMGN) today presente...cebo-controlled Phase 3 study evaluating the,effic...r the,treatment of anemia in patients with active ...("the 103 study"). Aranesp is not,approved for use...ts were presented in an oral session at the 2007 A...
... approach for the treatment,of early and metastati...wswire-FirstCall/ - AEterna,Zentaris Inc. , a glob... endocrine therapy and oncology, today presented a...ormone-releasing,hormone (GHRH) antagonist JMR-132... Cancer Research (AACR) Annual Meeting being held,...
Other Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 3
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...ty Massey Cancer Center have discovered a process ...cules containing platinum, which causes HIV and ca...the researchers to develop new drugs to fight HIV ...argeting proteins known as zinc fingers. In the M...
...at funds for wheelchair service from NHS has not r...ildren are losing out their hope due to lack of a ...wheelchair with most basic parts, was given due to...sh Me Around!’, highlights. Thus it calls for Gove...
...n (NBA) have entered into a partnership to support.... // The campaign, 'Unite for Children, Unite aga.../AIDS on children as well as impeding further spre...e know that our sport, indeed all sports, has an e...
...hetamine-like stimulant has a calming effect on ch...er (ADHD) // . A new study undertaken on rats, se...ly used to treat ADHD, appears to work by tweaking...acted by any stimuli from the outside world. The s...
Other Medicine News:Health News:New Research May Be Useful for Developing Drugs for HIV and Cancer 2Health News:Ritalin Could Help In Focussing The Mind 2
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: